Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 75 out of 100. Risk factors

Topic: Brain proteins, microglia and lab models

Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified. We report our comprehensive genome-wide association study as part of the International FTLD-TDP Whole-Genome Sequencing Consortium, including 985 patients and 3,153 controls compiled from 26 institutions/brain banks in North America, Europe and Australia, and meta-analysis with the Dementia-seq cohort. We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify TNIP1 as a novel FTLD-TDP risk factor. In subgroup analyzes, we further identify genome-wide significant loci specific to each of the three main FTLD-TDP pathological subtypes (A, B and C), as well as enrichment of risk loci in distinct tissues, brain regions, and neuronal subtypes, suggesting distinct disease aetiologies in each of the subtypes. Rare variant analysis confirmed TBK1 and identified C3AR1, SMG8, VIPR1, RBPJL, L3MBTL1 and ANO9, as novel subtype-specific FTLD-TDP risk genes, further highlighting the role of innate and adaptive immunity and notch signaling pathway in FTLD-TDP, with potential diagnostic and novel therapeutic implications. Here the authors identify TNIP1 as a risk factor for a fatal neurodegenerative disorder and discover specific genetic loci associated with the three main subtypes of this disorder. The findings highlight distinct disease mechanisms, emphasizing the roles of immunity and the notch signaling pathway.

Key findings

Why it matters

This genetic study of FTLD-TDP, a fatal neurodegenerative disorder distinct from Alzheimer's disease, confirmed UNC13A and identified TNIP1 as risk factors and found subtype-specific risk genes. These findings have potential diagnostic and therapeutic implications but do not yet provide a treatment or cure.

Study details

How this study scored 75/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 75 of 100.75 of 100 points earned25 not earned

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 985 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 A review of other studies — randomisation is not credited here
Times cited 3 / 7 Cited 25 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.3 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 14.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Edward B. Lee: h-index 79 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 52 institution(s) in 8 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40280976)
Free to read 2 / 2 Free to read
Total 75 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Pottier, C. P., Küçükali, F., Baker, M. C., Batzler, A., Jenkins, G. D., van Blitterswijk, M., et al. (2025). Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing. Nature Communications. https://doi.org/10.1038/s41467-025-59216-0

Vancouver

Pottier CP, Küçükali F, Baker MC, Batzler A, Jenkins GD, van Blitterswijk M, et al. Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing. Nature Communications. 2025. doi:10.1038/s41467-025-59216-0. PMID: 40280976.

BibTeX

@article{pottier2025-40280976,
  author  = {Pottier, Cyril P. and Küçükali, Fahri and Baker, Matt C. and Batzler, Anthony and Jenkins, Gregory D. and van Blitterswijk, Marka and Vicente, Cristina T. and De Coster, Wouter and others},
  title   = {{Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing}},
  journal = {Nature Communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-59216-0},
  pmid    = {40280976},
  url     = {https://doi.org/10.1038/s41467-025-59216-0}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Risk factors

Similar studies

More on Risk factors

See all studies in Risk factors →